

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)



(10) International Publication Number
WO 2024/227056 A1

(51) International Patent Classification:

C07C 237/20 (2006.01) C07D 213/75 (2006.01)
A61P 35/00 (2006.01) C07D 241/12 (2006.01)
C07C 311/51 (2006.01) C07D 257/04 (2006.01)
C07D 211/18 (2006.01) C07D 271/06 (2006.01)
C07D 211/34 (2006.01) C07D 271/10 (2006.01)
C07D 211/38 (2006.01) C07D 309/04 (2006.01)
C07D 213/06 (2006.01) C07D 317/62 (2006.01)
C07D 213/55 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/026616

(22) International Filing Date:

26 April 2024 (26.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/499,066 28 April 2023 (28.04.2023) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(71) Applicant: **METABOLON INC.**, [US/US]; 617 Davis Drive,
Suite 400, Morisville, North Carolina 27560 (US).

(72) Inventors: **SARANGARAJAN, Rangaprasad**; 454 Central
Street, Boylston, Massachusetts 01505 (US). **CHIM-
MANAMADA, Dinesh**; 78 Summer Street, Unit-4, Arlington,
Massachusetts 02474 (US). **JONES, Janice**; 462 Neodak
Road, Apex, North Carolina 27523 (US). **MCGIN-
LEY, Joseph Patrick**; 25 St Eithne Road, Cabra, Dublin 7,
Dublin, D07WR66 (IE). **SHERIDAN, Patricia A.**; 10 Sunset
Creek Circle, Chapel Hill, North Carolina 27516 (US).
SIMPSON, Joshua Bryan; 421 Glenview Lane, Durham,
North Carolina 27703 (US).

(74) Agent: **KENDALL, John** et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CNDP2 MODULATORS AND METHODS FOR THEIR USE

(57) Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination and/or stereoisomers (e.g., enantiomers and diastereomers) of the compound) that inhibit (e.g., antagonize) Carnosine Dipeptidase 2 (CNDP2). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) CNDP2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.



WO 2024/227056 A1